What Does Lilly and Covance R&D Deal Mean for Industry?

Yesterday's announcement that Eli Lilly had sold off its Greenfield, Indiana, R&D facility to Covance is perhaps not just a big deal, but really a bellwether move that may signal a trend of Big Pharma companies not just outsourcing aspects of their R&D operations but selling them off altogether. As the above-linked article suggests, the time for companies like Lilly to assume the role of financiers who aggregate data may be closer to reality. Your thoughts on the significance of the deal? We'll be keeping a close eye on this one, and include expert input in posts to come. --PWT
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


  • <p>One could say that supply chain security is the most critical issue facing drug manufacturers today—and perhaps facing our healthcare system as well. The supply chain is at the heart of healthcare’s greatest problems—drug counterfeiting and adulteration, shortages of key medicines, and of course escalating medical costs. Without security of supply, none of these challenges can be addressed.<a href="http://www.642-832.org">642-832</a> | <a href="http://www.642-902.org">642-902</a> | <a href="http://www.646-204.com">646-204</a> | <a href="http://www.ccsp.name">ccsp certification</a> | <a href="http://www.ccvp.cc">ccvp training</a> | <a href="http://www.ec0-350.com">ex0-350</a> | <a href="http://www.ex0-101.com">ex0-101</a> | <a href="http://www.mcitp.name">mcitp certification</a> | </p>


RSS feed for comments on this page | RSS feed for all comments